Global Vancomycin Strategic Business Report 2022: A Market Valued at $480.6 Million by 2027 Featuring Alchemia, Alvogen, Aphios, Cellceutix, CJ, Eli Lilly and Co, Enanta, Helix BioMedix, Lytix

DUBLIN, Jan. 4, 2023 /PRNewswire/ -- The "Vancomycin: Global Strategic Business Report" report has been added to  ResearchAndMarkets.com's offering.

Global Vancomycin Market to Reach $480.6 Million by 2027

The global market for Vancomycin estimated at US$367.4 Million in the year 2020, is projected to reach a revised size of US$480.6 Million by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027.

Lung Infection, one of the segments analyzed in the report, is projected to record a 5.1% CAGR and reach US$168.2 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Sepsis segment is readjusted to a revised 4.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $100.1 Million, While China is Forecast to Grow at 7.4% CAGR

The Vancomycin market in the U.S. is estimated at US$100.1 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$102 Million by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 2.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$64.4 Million by the year 2027.

Colitis & Intestinal Inflammation Segment to Record 2.8% CAGR

In the global Colitis & Intestinal Inflammation segment, USA, Canada, Japan, China and Europe will drive the 2.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$44.2 Million in the year 2020 will reach a projected size of US$52.8 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 3.1% CAGR through the analysis period.

What's New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Impact of Covid-19 and a Looming Global Recession
• Vancomycin - Global Key Competitors Percentage Market Share in 2022 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS (Total 12 Featured) 

• Alchemia Limited
• Alvogen
• Aphios Corporation
• Cellceutix Corporation
• CJ CheilJedang
• Eli Lilly and Company
• Enanta Pharmaceuticals
• Helix BioMedix
• LegoChem Biosciences
• Lytix Biopharma

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. REGIONALMARKET ANALYSIS

• United States
• Canada
• Japan
• China
• Europe
• France
• Germany
• Italy
• United Kingdom
• Spain
• Russia
• Rest Of Europe
• Asia-Pacific
• Australia
• India
• South Korea
• Rest Of Asia-Pacific
• Latin America
• Argentina
• Brazil
• Mexico
• Rest Of Latin America
• Middle East
• Iran
• Israel
• Saudi Arabia
• United Arab Emirates
• Rest Of Middle East
• Africa

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/7pjj7g

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets